Citigroup has recently initiated Celldex Therapeutics, Inc. (CLDX) stock to Buy rating, as announced on October 7, 2024, according to Finviz. Earlier, on September 30, 2024, Goldman had initiated the stock to Neutral, setting a price target of $45. Wolfe Research also reduced Peer Perform rating. Additionally, Stifel initiated Buy rating on June 18, 2024, with a target price of $58. Wolfe Research analysts, in their report published on June 11, 2024, also initiated Outperform rating and set a price target of $51 for Celldex Therapeutics, Inc.’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Celldex Therapeutics, Inc. (CLDX) Stock Trading Recap
On Friday, Celldex Therapeutics, Inc. (CLDX) stock saw a modest uptick, ending the day at $31.32 which represents a slight increase of $1.64 or 5.53% from the prior close of $29.68. The stock opened at $29.61 and touched a low of $29.55 during the day, reaching a high of $31.35. The volume of shares traded was 0.56 million falling short of the average volume of 0.98 million.
CLDX Stock Performance and Moving Averages
In recent trading, Celldex Therapeutics, Inc. (CLDX) stock price has shown some volatility, fluctuating 2.19% over the last five trades and -24.98% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -20.20%, and it has plunged by -20.81% in the previous three months. Currently, CLDX is trading at -10.73%, -14.30%, and -18.83% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, CLDX, a Healthcare sector stock, is trading -41.11% below its 52-week high but remains 41.66% above its 52-week low. The Average True Range (ATR) (14 days) of 2.29 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Celldex Therapeutics, Inc.’s Profitability and Valuation Ratios
Celldex Therapeutics, Inc.’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -1966.89% and a profit margin of -1809.40%, with a gross margin of -20.20%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Celldex Therapeutics, Inc.’s market capitalization stands at $2.08 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 250.14, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 2.55, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.14% of Celldex Therapeutics, Inc. (CLDX)’s shares, while financial institutions hold 103.45%.
Notable insider trades include Martin Samuel Bates, SVP AND CFO at Celldex Therapeutics, Inc. (CLDX), who sold 17172 shares on Jun 14 ’24, at $35.42 each, totaling $0.61 million. On Jun 14 ’24, Crowley Elizabeth, SR. VP & CPDO, sold 30000 shares for $34.87 each, amounting to $1.05 million. Additionally, on Jun 07 ’24, Crowley Elizabeth sold 15000 shares at $35.06 each, generating $0.53 million.
